Chugai Pharmaceutical Co., Ltd....and Nippon Shinyaku Co., Ltd....announced that Chugai obtained regulatory approval today from the Ministry of Health, Labour and Welfare (MHLW) for an anti-cancer agent/humanized anti-CD20 monoclonal antibody Gazyva® Intravenous Infusion 1000 mg [generic name: obinutuzumab (genetical recombination)] for an additional indication of CD20-positive chronic lymphocytic leukemia (including small lymphocytic lymphoma)....The approval is based on data including the phase III ELEVATE-TN study...